Yes — a federal judicial panel granted that request. The U.S. Judicial Panel on Multidistrict Litigation centralized Dupixent product-liability lawsuits into a single proceeding in the U.S.
District Court for the District of New Jersey, under an order dated June 4, 2026. The proceeding is formally known as MDL No. 3180, "In re: Dupixent (Dupilumab) Products Liability Litigation." It gathers lawsuits that allege the eczema and asthma drug Dupixent caused or accelerated a form of blood cancer, and it puts them in front of one judge for shared pretrial handling instead of scattering them across the country.
Official resources:
- Read the official notice from Harrismartin — Use this primary source to verify the official announcement.
- Read the official notice from Harrismartin — Use this primary source to verify the official announcement.
Table of Contents
- Why Plaintiffs Asked for Centralization
- Who Picked New Jersey, and Why
- What the Lawsuits Claim
- How Large Is the MDL and What Happens Next
- What Centralization Does and Doesn't Mean for Your Case
- Frequently Asked Questions
Why Plaintiffs Asked for Centralization
A motion asking the panel to centralize the cases was filed on February 13, 2026, on behalf of 15 plaintiffs whose lawsuits were spread across 12 different federal district courts. Filing the same type of claim in a dozen separate courts means duplicated discovery, conflicting schedules, and judges ruling on identical legal questions independently. Centralization — sometimes called an MDL, short for multidistrict litigation — solves that by sending every case to one judge for the shared pretrial work: document exchange, expert witness disputes, and early motions.
It does not merge the cases into one lawsuit or decide who wins; each plaintiff's case still gets its own trial later if it isn't settled first. Both sides in this instance agreed that combining the cases made sense. What they fought over was where.
Who Picked New Jersey, and Why
Dupixent's makers wanted the cases heard in a New York federal court, while some plaintiffs pushed for the Northern District of Georgia. The panel sided with neither, instead selecting the District of New Jersey. The panel assigned U.S.
District Judge Zahid N. Quraishi to oversee the consolidated proceeding. Judge Quraishi will manage every pretrial issue across the combined cases — including discovery disputes, expert testimony standards, and any early rulings that could shape how the litigation unfolds.
What the Lawsuits Claim
The lawsuits center on dupilumab, the injectable biologic drug sold as Dupixent and approved to treat eczema, asthma, and related inflammatory conditions. Plaintiffs allege the drug causes or accelerates cutaneous T-cell lymphoma, a cancer that affects the skin's immune cells. The named defendants are Regeneron Pharmaceuticals, Inc.
and Sanofi-Aventis U.S. LLC, the companies that develop and market the drug. The panel left one question open: whether lawsuits alleging other, non-cutaneous forms of T-cell lymphoma also belong in the MDL. That means the scope of what the proceeding ultimately covers could still expand.
📨 Get Free Mass Tort Guides Alerts
Free · No spam · Unsubscribe anytime
How Large Is the MDL and What Happens Next
At the MDL's creation, the panel transferred 15 pending actions into the New Jersey proceeding and flagged seven more potential "tag-along" cases for inclusion. By the panel's July 1, 2026 count, the docket had grown to 26 actions, according to a review of the case count reported by the Tavrn legal blog.
Judge Quraishi's Initial Procedure Order No. 1, filed June 11, 2026, formally consolidated the listed cases for pretrial purposes and set up an automatic process: any future tag-along case is folded into the MDL without a separate motion, according to a copy of the order. That same order scheduled an initial case management conference for October 1, 2026, with the agenda built around the Manual for Complex Litigation, Fourth, and Federal Rule of Civil Procedure 16.1.
- The MDL number is 3180, housed in the District of New Jersey.
- Judge Zahid N. Quraishi presides over pretrial matters.
- New cases alleging the same injury can be added automatically as tag-alongs.
- An initial case management conference was set for October 1, 2026.
What Centralization Does and Doesn't Mean for Your Case
Centralization is a procedural step, not a verdict. It groups similar lawsuits so discovery and pretrial motions happen once instead of repeatedly, but it does not establish that Dupixent causes lymphoma. Dupixent remains FDA-approved and on the market, and the causal claims against it remain unproven allegations, according to Lieff Cabraser.
Anyone who took Dupixent and was later diagnosed with cutaneous T-cell lymphoma, and who believes the two may be connected, can have an existing or future lawsuit folded into MDL No. 3180 as a tag-along case rather than filing in a separate court. The case still proceeds individually toward its own outcome — settlement or trial — once shared pretrial work in front of Judge Quraishi is complete.
Frequently Asked Questions
Is MDL No. 3180 a class action?
No. It consolidates pretrial proceedings for individual lawsuits; each case keeps its own outcome rather than being merged into one claim.
Can a new Dupixent lymphoma lawsuit still join the New Jersey proceeding?
Yes. Judge Quraishi's Initial Procedure Order No. 1 allows future tag-along cases to be added automatically, without a separate motion.
Does this mean Dupixent has been found to cause cancer?
No. Centralization only organizes pretrial litigation; Dupixent remains FDA-approved, and the causal claims remain unproven allegations, per Lieff Cabraser.
You Might Also Like
- What Is New With Damages Mass Tort Litigation in October 2026? Latest court filings and agency notices and Key Takeaways
- Who Qualifies for a Gabapentin Dementia Lawsuit Claim?
- What Happens to an Individual Lawsuit When Part of an MDL Settles?